Literature DB >> 34088997

Superficial ALK-rearranged myxoid spindle cell neoplasm: a cutaneous soft tissue tumor with distinctive morphology and immunophenotypic profile.

Steven D Billings1, Jennifer S Ko2, Josephine K Dermawan1, Elizabeth M Azzato1, John R Goldblum1, Brian P Rubin1.   

Abstract

Gene rearrangements involving the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase gene have been identified in various neoplasms, including inflammatory myofibroblastic tumor and epithelioid fibrous histiocytoma. We present an ALK-rearranged cutaneous soft tissue tumor with unique morphologic and immunophenotypic features that are not shared by other entities with ALK rearrangements. The six cases involved two females and four males, aged 18-84 (mean 51) years old. Three tumors were on the back and three on the lower extremities (thigh, knee, shin); ranging from 0.5 to 5.6 (mean 2.1) cm. Four were confined to the dermis; two involved the subcutis. All six cases were characterized by the presence of spindled to ovoid cells arranged in concentric whorls and cords against a myxoid to myxohyaline stroma and relatively cellular aggregates of plump ovoid to epithelioid cells. Four cases showed distinct hyalinized blood vessels. Both cases that involved the subcutis showed peripheral lipofibromatosis-like areas. Tumor-infiltrating lymphocytes were absent to moderate. Severe cytologic atypia or conspicuous mitotic activity was not identified. Immunohistochemically, all tumors diffusely expressed ALK (D5F3) and CD34. All but one tumor was diffusely positive for S100 protein. All tumors were negative for EMA, AE1/AE3, SMA, and SOX10. Next-generation sequencing revealed ALK fusions with FLNA (3 cases), MYH10 (2 cases), and HMBOX1 (1 case) as the partner genes. In all six cases, the breakpoints involved exon 20 of ALK, which preserves the receptor tyrosine kinase domains of ALK in the fusion product. Of the four cases with limited follow-up information (2-18 months), none recurred. In conclusion, we report an ALK-rearranged cutaneous soft tissue tumor characterized by the presence of myxoid spindle cell whorls and cords, and co-expression of ALK, CD34, and frequently S100 protein, we term "superficial ALK-rearranged myxoid spindle cell neoplasm".
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34088997     DOI: 10.1038/s41379-021-00830-w

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  42 in total

1.  ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.

Authors:  Leona A Doyle; Adrián Mariño-Enriquez; Christopher D M Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2015-04-10       Impact factor: 7.842

2.  Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases.

Authors:  Brendan C Dickson; David Swanson; George S Charames; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

3.  A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.

Authors:  Sapna M Amin; Alexandra M Haugh; Christina Y Lee; Bin Zhang; Jeffrey A Bubley; Emily A Merkel; Anna Elisa Verzì; Pedram Gerami
Journal:  Am J Surg Pathol       Date:  2017-04       Impact factor: 6.394

4.  Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor.

Authors:  J A Bridge; M Kanamori; Z Ma; D Pickering; D A Hill; W Lydiatt; M Y Lui; G W Colleoni; C R Antonescu; M Ladanyi; S W Morris
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

5.  A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes.

Authors:  Albert J H Suurmeijer; Brendan C Dickson; David Swanson; Lei Zhang; Yun-Shao Sung; Paolo Cotzia; Christopher D M Fletcher; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2018-10-01       Impact factor: 5.006

6.  Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3.

Authors:  M Shiota; J Fujimoto; T Semba; H Satoh; T Yamamoto; S Mori
Journal:  Oncogene       Date:  1994-06       Impact factor: 9.867

Review 7.  The role of the ALK receptor in cancer biology.

Authors:  B Hallberg; R H Palmer
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

8.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

Review 9.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

10.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

View more
  2 in total

Review 1.  Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature.

Authors:  Shefali Chopra; Nolan Maloney; Wei Lien Wang
Journal:  Brain Tumor Pathol       Date:  2021-11-06       Impact factor: 3.298

2.  Primitive Cutaneous (P)erivascular (E)pithelioid (C)ell Tumour (PEComa): A New Case Report of a Rare Cutaneous Tumor.

Authors:  Gerardo Cazzato; Anna Colagrande; Lucia Lospalluti; Lucia Pacello; Teresa Lettini; Francesca Arezzo; Vera Loizzi; Carmelo Lupo; Nadia Casatta; Gennaro Cormio; Eugenio Maiorano; Giuseppe Ingravallo; Leonardo Resta
Journal:  Genes (Basel)       Date:  2022-06-26       Impact factor: 4.141

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.